Pharsight

Nesina generic

Nesina is an anti-diabetic drug owned by Takeda Pharms Usa. The active ingredient in Nesina is alogliptin benzoate. With a total of 4 held patents, its date of first market authorization is 25 January, 2013 and is available in tablet-shaped oral dosage forms.

When will Nesina generic be available?

Nesina's generic release date is projected to be after 16 June, 2029. Its last patent, titled 'Tablet preparation without causing a tableting trouble', is expected to expire on the same date.

Nesina uses

Nesina can be used as a method of treating diabetes. Its effectiveness is linked to the role of its active ingredient, Alogliptin, a compound renowned for its anti-diabetic properties.

Nesina patent expiration

Nesina holds a total of 4 patents, with the last one, titled 'Tablet preparation without causing a tableting trouble', expiring on 16 June, 2029. Hence, the likelihood of a Nesina generic version will possibly come into consideration after this date. Below are the details of the patent:

Nesina dosage

Want to ask something?